Idogen receives approval from the Swedish Medical Products Agency for its clinical phase 1/2a study
Idogen AB (publ) has received the Swedish Medical Products Agency's approval for its clinical phase 1/2a study for IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to their vital treatment with coagulation factor VIII. The company is expected to be able to begin patient recruitment during the second quarter of 2022 after the Medical Products Agency's formal approval of the study's Swedish clinic. Idogen develops tolerogenic cell therapies where the goal is to prevent an unwanted activation of the immune system. For